|
1
|
Huang TW, Lin KF, Lee CH, Chang H, Lee SC
and Shieh YS: The role of thyroid transcription factor-1 and tumor
differentiation in resected lung adenocarcinoma. Sci Rep.
7:142222017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vieira A and Ugalde Figueroa P: Anatomic
bisegmentectomy for synchronous lung adenocarcinoma. J Vis Surg.
3:642017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang T, Chen L, Zhang S, Xu Y, Fan Y and
Zhang L: Effects of high-intensity focused ultrasound on
cisplatin-resistant human lung adenocarcinoma in vitro and in vivo.
Acta Biochim Biophys Sin (Shanghai). 49:1092–1098. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu H, Meng S, Xu Q, Wang X, Wang J, Gong
R, Song Y, Duan Y and Zhang Y: Gene expression profiling of lung
adenocarcinoma in Xuanwei, China. Eur J Cancer Prev. 25:508–517.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ni J, Zhou LL, Ding L, Zhao X, Cao H, Fan
F, Li H, Lou R, Du Y, Dong S, et al: PPARγ agonist efatutazone and
gefitinib synergistically inhibit the proliferation of
EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt
pathway. Exp Cell Res. 361:246–256. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bernhardt D, Adeberg S, Bozorgmehr F,
Opfermann N, Hörner-Rieber J, König L, Kappes J, Thomas M,
Unterberg A, Herth F, et al: Outcome and prognostic factors in
single brain metastases from small-cell lung cancer. Strahlenther
Onkol. 194:98–106. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim CS and Jeter MD: Radiation therapy,
early stage non-small cell lung cancer. StatPearls. Treasure.
(Island (FL)). 2018.
|
|
8
|
Li-Ming X, Zhao LJ, Simone CB II, Cheng C,
Kang M, Wang X, Gong LL, Pang QS, Wang J, Yuan ZY and Wang P:
Receipt of thoracic radiation therapy and radiotherapy dose are
correlated with outcomes in a retrospective study of three hundred
and six patients with extensive stage small-cell lung cancer.
Radiother Oncol. 125:331–337. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peng Y, Ren W, Wang H, Li M, Feng Z and
Peng Z: Surgical treatment is an effective approach for patients
with synchronous multiple primary lung cancers. J Cancer Res Ther.
13:702–706. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nhat Tran, Alipourfard B, Abhyankar V,
Nguyen K, Weidanz J and Gao J: Improved microRNA biomarkers for
pathological stages in lung adenocarcinoma via clustering of
dysregulated microRNA-target associations. Conf Proc IEEE Eng Med
Biol Soc. 2017:2708–2711. 2017.PubMed/NCBI
|
|
11
|
Chang SM and Hu WW: Long non-coding RNA
MALAT1 promotes oral squamous cell carcinoma development via
microRNA-125b/STAT3 axis. J Cell Physiol. 233:3384–3396. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bian T, Jiang D, Liu J, Yuan X, Feng J, Li
Q, Zhang Q, Li X, Liu Y and Zhang J: miR-1236-3p suppresses the
migration and invasion by targeting KLF8 in lung adenocarcinoma
A549 cells. Biochem Biophys Res Commun. 492:461–467. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sui J, Yang RS, Xu SY, Zhang YQ, Li CY,
Yang S, Yin LH, Pu YP and Liang GY: Comprehensive analysis of
aberrantly expressed microRNA profiles reveals potential biomarkers
of human lung adenocarcinoma progression. Oncol Rep. 38:2453–2463.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berrout J, Kyriakopoulou E, Moparthi L,
Hogea AS, Berrout L, Ivan C, Lorger M, Boyle J, Peers C, Muench S,
et al: TRPA1-FGFR2 binding event is a regulatory oncogenic driver
modulated by miRNA-142-3p. Nat Commun. 8:9472017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yan W, Wu Q, Yao W, Li Y, Liu Y, Yuan J,
Han R, Yang J, Ji X and Ni C: MiR-503 modulates
epithelial-mesenchymal transition in silica-induced pulmonary
fibrosis by targeting PI3K p85 and is sponged by lncRNA MALAT1. Sci
Rep. 7:113132017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pan T, Chen W, Yuan X, Shen J, Qin C and
Wang L: miR-944 inhibits metastasis of gastric cancer by preventing
the epithelial-mesenchymal transition via MACC1/Met/AKT signaling.
FEBS Open Bio. 7:905–914. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang J, Zheng C and Shao J, Chen L, Liu X
and Shao J: Overexpression of eEF1A1 regulates G1-phase progression
to promote HCC proliferation through the STAT1-cyclin D1 pathway.
Biochem Biophys Res Commun. 494:542–549. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hiller J, Hagl B, Effner R, Puel A,
Schaller M, Mascher B, Eyerich S, Eyerich K, Jansson AF, Ring J, et
al: STAT1 gain-of-function and dominant negative STAT3 mutations
impair IL-17 and IL-22 immunity associated with CMC. J Invest
Dermatol. 138:711–714. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Collins-McMillen D, Stevenson EV, Kim JH,
Lee BJ, Cieply SJ, Nogalski MT, Chan GC, Frost RW III, Spohn CR and
Yurochko AD: HCMV utilizes a non-traditional STAT1 activation
cascade via signaling through EGFR and integrins to efficiently
promote the motility, differentiation, and polarization of infected
monocytes. J Virol pii. JVI.00622-17. 2017. View Article : Google Scholar
|
|
20
|
Liu R, Lu Z, Gu J, Liu J, Huang E, Liu X,
Wang L, Yang J, Deng Y, Qian J, et al: MicroRNAs 15A and 16-1
activate signaling pathways that mediate chemotaxis of immune
regulatory B cells to colorectal tumors. Gastroenterology.
154:637–651.e7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Li X, Tan F, Yu N and Pei H:
STAT1 inhibits MiR-181a expression to suppress colorectal cancer
cell proliferation through PTEN/Akt. J Cell Biochem. 118:3435–3443.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang M, Du Y, Lu R, Shu Y, Zhao W, Li Z,
Zhang Y, Liu R, Yang T, Luo S, et al: Cholesterol retards
senescence in bone marrow mesenchymal stem cells by modulating
autophagy and ROS/p53/p21Cip1/Waf1 pathway. Oxid Med
Cell Longev. 2016:75243082016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Daugherty A, Hegele RA, Mackman N, Rader
DJ, Schmidt AM and Weber C: Complying with the national institutes
of health guidelines and principles for rigor and reproducibility:
Refutations. Arterioscler Thromb Vasc Biol. 36:1303–1304. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li M, Liang Z, He S, Zeng Y, Jing Y, Fang
W, Wu K, Wang G, Ning X, Wang L, et al: Genome-wide identification
of leaf abscission associated microRNAs in sugarcane (Saccharum
officinarum L.). BMC Genomics. 18:7542017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao S, Gao X, Zang S, Li Y, Feng X and
Yuan X: MicroRNA-383-5p acts as a prognostic marker and inhibitor
of cell proliferation in lung adenocarcinoma by cancerous inhibitor
of protein phosphatase 2A. Oncol Lett. 14:3573–3579. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhuang L, Shou T, Li K, Gao CL, Duan LC,
Fang LZ, Zhang QY, Chen ZN, Zhang C, Yang ST and Li GF:
MicroRNA-30e-5p promotes cell growth by targeting PTPN13 and
indicates poor survival and recurrence in lung adenocarcinoma. J
Cell Mol Med. 21:2852–2862. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Chen Y, Yun H, Liu Z, Su M and
Lai R: STAT1β enhances STAT1 function by protecting STAT1α from
degradation in esophageal squamous cell carcinoma. Cell Death Dis.
8:e30772017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu Y, Wang L, Gu J, Qu K and Wang Y:
Identification of microRNA differentially expressed in three
subtypes of non-small cell lung cancer and in silico functional
analysis. Oncotarget. 8:74554–74566. 2017.PubMed/NCBI
|
|
30
|
Li W, Yang W, Liu Y, Chen S, Chin S, Qi X,
Zhao Y, Liu H, Wang J, Mei X, et al: MicroRNA-378 enhances
inhibitory effect of curcumin on glioblastoma. Oncotarget.
8:73938–73946. 2017.PubMed/NCBI
|
|
31
|
Zhang QL, Zhu QH, Zhang F, Xu B, Wang XQ
and Chen JY: Transcriptome-wide analysis of immune-responsive
microRNAs against poly (I:C) challenge in Branchiostoma belcheri by
deep sequencing and bioinformatics. Oncotarget. 8:73590–73602.
2017.PubMed/NCBI
|
|
32
|
Yang Y, Ji C, Guo S, Su X, Zhao X, Zhang
S, Liu G, Qiu X, Zhang Q, Guo H and Chen H: The miR-486-5p plays a
causative role in prostate cancer through negative regulation of
multiple tumor suppressor pathways. Oncotarget. 8:72835–72846.
2017.PubMed/NCBI
|
|
33
|
Yan S, Dang G, Zhang X, Jin C, Qin L, Wang
Y, Shi M, Huang H and Duan Q: Downregulation of circulating
exosomal miR-638 predicts poor prognosis in colon cancer patients.
Oncotarget. 8:72220–72226. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fawzy MS, Toraih EA, Ibrahiem A,
Abdeldayem H, Mohamed AO and Abdel-Daim MM: Evaluation of
miRNA-196a2 and apoptosis-related target genes: ANXA1, DFFA and
PDCD4 expression in gastrointestinal cancer patients: A pilot
study. PLoS One. 12:e01873102017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wen L, Li Y, Jiang Z, Zhang Y, Yang B and
Han F: miR-944 inhibits cell migration and invasion by targeting
MACC1 in colorectal cancer. Oncol Rep. 37:3415–3422. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
He Z, Xu H, Meng Y and Kuang Y: miR-944
acts as a prognostic marker and promotes the tumor progression in
endometrial cancer. Biomed Pharmacother. 88:902–910. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu Y, Zhang J, Sun X, Su Q and You C:
Down-regulation of miR-29b in carcinoma associated fibroblasts
promotes cell growth and metastasis of breast cancer. Oncotarget.
8:39559–39570. 2017.PubMed/NCBI
|
|
38
|
Borsini A, Cattaneo A, Malpighi C, Thuret
S, Harrison NA; MRC ImmunoPsychiatry Consortium, ; Zunszain PA and
Pariante CM: Interferon-alpha reduces human hippocampal
neurogenesis and increases apoptosis via activation of distinct
STAT1-dependent mechanisms. Int J Neuropsychopharmacol. 21:187–200.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Carbotti G, Nikpoor AR, Vacca P, Gangemi
R, Giordano C, Campelli F, Ferrini S and Fabbi M: IL-27 mediates
HLA class I up-regulation, which can be inhibited by the IL-6
pathway, in HLA-deficient small cell lung cancer cells. J Exp Clin
Cancer Res. 36:1402017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang Y and Liu Z: STAT1 in cancer: Friend
or foe? Discov Med. 24:19–29. 2017.PubMed/NCBI
|
|
41
|
Xi J, Huang Q, Wang L, Ma X, Deng Q, Kumar
M, Zhou Z, Li L, Zeng Z, Young KH, et al: miR-21 depletion in
macrophages promotes tumoricidal polarization and enhances PD-1
immunotherapy. Oncogene. 37:3151–3165. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li J, He X, Wei W and Zhou X: MicroRNA-194
promotes osteoblast differentiation via downregulating STAT1.
Biochem Biophys Res Commun. 460:482–488. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li L, Li W, Chen N, Zhao H, Xu G, Zhao Y,
Pan X, Zhang X, Zhou L, Yu D, et al: FLI1 exonic circular RNAs as a
novel oncogenic driver to promote tumor metastasis in small cell
lung cancer. Clin Cancer Res. Nov 14–2018.(Epub ahead of
print).
|
|
44
|
Gujam FJ, McMillan DC and Edwards J: The
relationship between total and phosphorylated STAT1 and STAT3
tumour cell expression, components of tumour microenvironment and
survival in patients with invasive ductal breast cancer.
Oncotarget. 7:77607–77621. 2016. View Article : Google Scholar : PubMed/NCBI
|
